Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia
Authors:
- Ana Luiza de Melo RodriguesARAna Luiza de Melo Rodrigues
- Adriana SeberASAdriana Seber
- Luciana DominguesLDLuciana Domingues
- Victor Gottardello ZecchinVZVictor Gottardello Zecchin
- Maria Lúcia de Martino LeeMLMaria Lúcia de Martino Lee
- Liane DaudtLDLiane Daudt
- Luiza de SouzaLSLuiza de Souza
- Adriana Martins de SousaASAdriana Martins de Sousa
- Antonella Adriana ZanetteAZAntonella Adriana Zanette
- Carla NolascoCNCarla Nolasco
- Virgínio ClimacoVCVirgínio Climaco
- Ana Carolina RibeiroARAna Carolina Ribeiro
Open Access
- 8 January 2025
- journal article
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Abstract
Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.Keywords
This publication has 51 references indexed in Scilit:
- Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndromePediatric Blood & Cancer, 2024
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid LeukemiaJAMA Oncology, 2020
- Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in JapanPediatric Blood & Cancer, 2020
- The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft‐versus host disease after stem‐cell transplantation from unrelated donorsAmerican Journal of Hematology, 2017
- Current Management of Childhood Acute Myeloid LeukemiaPediatric Drugs, 2016
- Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling DonorsTransplantation and Cellular Therapy, 2015
- Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid LeukemiaTransplantation and Cellular Therapy, 2013
- Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Patients with Treatment-Related Myelodysplastic Syndrome or Acute Myelogenous LeukemiaTransplantation and Cellular Therapy, 2012
- Hematopoietic Stem Cell Transplant for Pediatric Acute Promyelocytic LeukemiaTransplantation and Cellular Therapy, 2008
- Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Hematologic MalignanciesTransplantation and Cellular Therapy, 2007